ACIP	Advisory Committee on Immunization Practices
Att	Attenuated
Ca	Cold-adapted
CBD	Cap-binding domain
CEIRS	Centers of Excellence for Influenza Research and Surveillance
CIV	Canine influenza virus(es)
CKTC	Chicken kidney tissue culture
cRNA	Complementary RNA
eIF4E	Eukaryotic initiation factor 4E
EIV	Equine influenza virus(es)
FDA	Food and Drug Administration
HA	Hemagglutinin
HPAIV	Highly pathogenic avian influenza virus(es)
IAV	Influenza A virus(es)
IBV	Influenza B virus(es)
ICV	Influenza C virus(es)
IDV	Influenza D virus(es)
IFN	Interferon
IIV	Inactivated influenza vaccine(s)
kDa	Kilodalton
LAIV	Live attenuated influenza vaccine(s)
LAV	Live attenuated vaccine(s)
Len/17	A/Leningrad/134/17/57 H2N2 LAIV
Len/47	A/Leningrad/134/47/57 H2N2 LAIV
M1	Matrix protein 1
M2	Matrix protein 2
MDV	Master donor virus
NA	Neuraminidase
NAbs	Neutralizing antibodies
NCR	Non-coding region
NEP	Nuclear export protein
NIAID	National Institute of Allergy and Infectious Diseases
NIH	National Institutes of Health
NLS	Nuclear localization signal
NP	Nucleoprotein
NS1	Non-structural protein 1
NYICE	New York Influenza Center of Excellence
ORF	Open reading frame
PA	Polymerase acid protein
PB1	Polymerase basic protein 1
PB2	Polymerase basic protein 2
PFU	Plaque forming units
pH1N1	Pandemic A/California/04/09 H1N1 influenza virus
PR8	A/Puerto Rico/8/34 H1N1 influenza virus
RBD	Receptor binding domain
RdRp	Viral RNA-dependent RNA polymerase
SA	Sialic acid
Ts	Temperature-sensitive
vRNA	Viral RNA
vRNP	Viral ribonucleoprotein
US	United States
USSR	Union of Soviet Socialist Republics
WHO	World Health Organization
WSN	A/WSN/33 H1N1 influenza virus
WT	Wild-type
X31	Reassortant influenza virus containing the HA and NA genes of A/Hong Kong/1/68 H3N2 in the background of influenza PR8 virus